Byung Suk Lim
Gerontology · Edison, NJNPI 1093321663
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 229 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 28 manufacturers, the largest accounting for just 16.2% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,464, 2.4 times the $609 reported in 2022. Among gerontology clinicians in NJ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 229 payments — averaging $18.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$675
- Lilly USA, LLC$660
- Boehringer Ingelheim$554
- Sanofi-aventis U.S. LLC$343
- Dexcom, Inc.$271
- AstraZeneca$243
- plus $1K from 22 others
What the payments were for
- Food & beverage$4,175100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 54 | $675 |
| Lilly USA, LLC | 36 | $660 |
| Boehringer Ingelheim | 16 | $554 |
| Sanofi-aventis U.S. LLC | 13 | $343 |
| Dexcom, Inc. | 13 | $271 |
| AstraZeneca(2 entities) | 16 | $243 |
| Xeris Pharmaceuticals, Inc. | 15 | $231 |
| Corcept Therapeutics | 8 | $169 |
| Medtronic | 6 | $167 |
| AbbVie | 9 | $145 |
| Mannkind Corporation | 8 | $122 |
| Amgen | 6 | $98 |
| Tandem Diabetes Care, Inc. | 2 | $52 |
| Recordati_rare_diseases_inc. | 3 | $49 |
| IBSA Pharma Inc. | 3 | $48 |
| Insulet Corporation | 2 | $43 |
| Azurity Pharmaceuticals, Inc. | 2 | $38 |
| Astellas Pharma US Inc | 2 | $35 |
| Radius Health, Inc. | 2 | $34 |
| Vivus LLC | 2 | $34 |
| Cequr Corporation | 2 | $32 |
| Amneal Pharmaceuticals LLC | 2 | $30 |
| Amarin Pharma, Inc. | 2 | $25 |
| Ascendis Pharma Endocrinology Inc | 1 | $18 |
| Ultragenyx Pharmaceutical Inc. | 1 | $17 |
| Neurocrine Biosciences, Inc. | 1 | $15 |
| Acella Pharmaceuticals, LLC | 1 | $15 |
| Amphastar Pharmaceuticals, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,175 in reported general payments places this provider in the 95th percentile of 374 gerontology providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 73 | $90,652 |
| MounjaroTirzepatide | 54 | $64,599 |
| FarxigaDapagliflozin Propanediol | 36 | $47,950 |
| TradjentaLinagliptin | 50 | $47,416 |
| JardianceEmpagliflozin | 31 | $41,580 |
| TrulicityDulaglutide | 21 | $27,986 |
| JanuviaSitagliptin Phosphate | 15 | $21,355 |
| WegovySemaglutide | 11 | $14,154 |
| Tresiba Flextouch U-100Insulin Degludec | 13 | $5,310 |
| JanumetSitagliptin Phos/Metformin Hcl | 14 | $4,378 |
| Humalog Kwikpen U-100Insulin Lispro | 19 | $3,695 |
| Nano 2nd Gen Pen NeedlePen Needle, Diabetic | 37 | $3,677 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 22 | $2,592 |
| SynthroidLevothyroxine Sodium | 31 | $2,123 |
| Levothyroxine Sodium | 111 | $1,299 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Wegovy | $675 | $104,80684 claims |
| Lilly USA, LLCMounjaro, Trulicity | $660 | $92,58575 claims |
| Boehringer IngelheimTradjenta, Jardiance | $554 | $88,99681 claims |
| AstraZenecaFarxiga | $243 | $47,95036 claims |
| AbbVieSynthroid | $145 | $2,12331 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $30 | $1,299111 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 374 gerontology providers in New Jersey.
Other gerontology in Edison
- Elizabeth CostanzaEdison$3K
- Dana JonesTeaneck$150K
- Jennifer FoxFlemington$76K
- Susan HermidaBrick$33K
- Jihane SaadeNorth Bergen$9K
- Joseph RudolphCamden$8K
- Jennifer LernerNew Brunswick$7K
- Josephine MachadoNew Brunswick$7K
- Remya JamesNew Brunswick$7K
- Anna HaEnglewood$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.